The FDA has approved oral semaglutide (Rybelsus) 7 mg and 14 mg tablets to lower the risk of cardiovascular death, heart attack, or stroke in high-risk adults with type 2 diabetes-marking the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback